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Gaucher disease is the first lysosomal storage disease for which specific therapy became avail-
able. Over 4800 patients have been treated with enzyme replacement therapy. Analysis of
Gaucher disease registry data has outlined the clinical heterogeneity of the disease and the dif-
ferent responses to treatment from patient to patient, and for different organs. This variability in
clinical response justifies the development of a severity score index to assess disease activity,
stage and prognosis, and to quantify the effects of treatment.
Design and Methods
The new scoring system proposed here, the “Gaucher Disease Severity Score Index – Type I”
(GauSSI-I), is based on the clinical experience of the authors and an extensive literature review,
including data from the International Gaucher Registry. In particular for skeletal disease, all the
available scoring systems have been reviewed and compared in order to provide a skeletal scor-
ing system that allows use of any of the different methods on an equivalent basis.
Results
The new scoring system, GauSSI-I, was developed. Six specific domains, in which different items
were scored according to their impact on morbidity, were characterized. GauSSI-I was evaluat-
ed in 53 type I Gaucher patients treated with imiglucerase, and it was compared to the Zimran
score, the only severity index score so far available.
Conclusions
The GauSSI-I is a reliable method for staging the severity of adult type I Gaucher disease, and
it is more sensitive than the Zimran score for monitoring the response to treatment.
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Introduction
Gaucher disease is an autosomal recessive lysosomal
storage disorder, in which a deficiency of the enzyme
glucocerebrosidase leads to the accumulation of gluco-
cerebroside in the lysosomes of monocytes and macro-
phages.1-2
The disease has traditionally been classified into three
clinical phenotypes: type I – adult, non-neuronopathic;
type II – infantile or acute neuronopathic form (rapidly
progressive neurovisceral storage disease, with death
during infancy); and type III – juvenile or chronic neu-
ronopathic (less rapidly progressive neurovisceral stor-
age disease).
Type I is the most prevalent form of Gaucher disease
with an incidence of approximately 1/40-60,000 in the
general population, and 1/450 in the Ashkenazi Jewish
population. It is a chronic multiorgan disorder character-
ized by the presence of apparently disconnected symp-
toms and signs, which may encompass one or more of
the following: splenomegaly, hepatomegaly, (pan)cyto-
penia, various bone manifestations and pulmonary dis-
ease. Central neurological involvement is rare and dif-
ferent and less severe than in type II and type III
Gaucher disease.
The phenotypic expression and the clinical course of
the disease are extremely heterogeneous, varying in
severity among individuals as well as presenting with
different degrees of involvement of different organs in
the same individual.
Enzyme replacement therapy (ERT), available since
the early 1990s, is an effective treatment for Gaucher
disease, and today imiglucerase is the acknowledged
standard of care for the treatment of patients with
Gaucher type I and type III disease. Substrate reduction
therapy (miglustat)3-6 has recently been approved for the
treatment of symptomatic type I patients with mild to
moderate disease for whom ERT is unsuitable or not a
therapeutic option. Future treatments, including small
molecule chaperones and gene therapy, are still under
investigation.7,8
The availability of different therapies has increased
the need for a methodology that is specific and sensitive
enough to assess and monitor disease severity in indi-
vidual patients, and to enable measurements of disease
progression and response to treatment.
The only currently available index to estimate the
severity of Gaucher disease was produced by Zimran et
al. in 1992,9 just at the beginning of the ERT era, and
was originally designed to correlate Gaucher genotypes
with phenotypes of the disease. Emerging data concern-
ing clinical heterogeneity and different responses to
treatment from different organs, as well as the availabil-
ity of new imaging techniques and of new biological
markers to quantify burden of disease, justify the devel-
opment of a new score.10
Design and Methods
The new scoring system, the Gaucher Disease Severity
Score Index – Type I (GauSSI-I), is based on the clinical
experience of the authors, combined with an extensive
review of the relevant literature (including data from
the International Gaucher Registry, an observational
database established in 1991). An adjusted Delphi tech-
nique was used to reach a consensus on the severity
score. First, each participant listed all relevant disease
manifestations, which were then collectively reviewed.
The relative importance of the different domains, and
the individual signs or symptoms included therein, was
agreed upon. 
Skeletal domain
Skeletal manifestations are a major problem in
Gaucher disease. Bone pain, osteopenia and bone mar-
row infiltration (which are reversible following ERT),
have a significant impact on the patients’ wellbeing. In
addition, irreversible complications such as osteonecro-
sis, osteolysis, permanent deformities from vertebral
crush fractures or other pathological fractures, and sec-
ondary arthropathy, limit mobility, and affect quality of
life substantially. As bone turnover is a slow process,11
the full extent of manifestations, especially in the min-
eral bone compartment, develops over a number of
years, and the skeletal response to ERT is reported to
be slower than the hematologic and visceral responses.
Skeletal changes were initially diagnosed by standard
planar X-ray specifically showing gross changes in the
mineral component of bone. Bone mineral density
(BMD), either in the whole body or at selected skeletal
sites (most commonly the lumbar spine and hip), is
measured by dual-energy X-ray absorptiometry
(DEXA). To evaluate the degree of bone marrow infil-
tration by Gaucher cells, several imaging methods have
been developed, including magnetic resonance imaging
(MRI) and scintigraphic imaging. At least seven differ-
ent (semi-)quantitative scoring systems can be
employed for magnetic resonance evaluation of the
bone marrow.12-17 Among several methods proposed in
the past18 two different scintigraphic approaches are
applicable routinely: 99mTc-radiocolloid bone marrow
scintigraphy and scintigraphy with 99mTc-sestamibi.19,20
Thus, at least nine different bone marrow infiltration
scores (seven MRI-based, two scintigraphy-based) can
be employed to assess severity of basically the same
pathological event: bone marrow infiltration by
Gaucher cells. In order to include a skeletal score in the
GauSSI-I, independently of the technique used to
assess bone marrow infiltration, all the bone marrow
infiltration scoring systems so far available were com-
paratively analyzed and stratified to make them equiv-
alent to each other (normalization process). Only one
normalized score corresponding to bone marrow
involvement and another one pertaining to mineral
bone involvement were used to develop the final over-
all GauSSI-I skeletal score of any given patient.
Normalization was achieved by assigning the lowest
value (0) to the absence of skeletal abnormalities, and
scores 1 to 3 for increasing severity. The original scores
were thus regrouped into four new categories (0 to 3)
based on analogy of the parameters describing the
severity of the abnormalities, which were graded as ini-
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tial/mild (score 1), intermediate (score 2), and severe
(score 3). In addition, an assessment for the presence of
irreversible skeletal disease was included in the skeletal
domain by adding points for the presence of
osteonecrosis or pathological fractures.
Bone marrow infiltration subdomain
The categorization proposed for normalizing the var-
ious bone marrow infiltration scores for the bone mar-
row component is detailed in Table 1, for both MRI
evaluation and scintigraphic evaluation. Preliminary
validation of the approach employed for normalization
of the various scores of bone marrow infiltration in a
group of 44 adult patients with type I Gaucher disease
was recently presented for the Vertebra Disc Ratio
(VDR) score, for the Terk score, for the bone marrow
burden score, for the Spanish MRI score, and for the
scintigraphic 99mTc-sestamibi score.21 Scores were blind-
ly and independently assigned by a panel of radiolo-
gists expert in Gaucher disease. There was a strong
relationship between the scores when analyzing the
original data (Chrombach’s α measure of agreement
was between 0.82-0.85). Such a relationship was main-
tained, and in some cases even improved, after normal-
ization of the scores (Chrombach’s α between 0.85-
0.87, p between 0.0378 and <0.0001). 
Bone mineral subdomain
As for the scoring system developed for marrow infil-
tration, the rationale for grading bone (mineral) struc-
tural changes is based on stratification into four cate-
gories: absence of lesions (score 0), mild abnormalities
(grade 1), abnormalities of intermediate severity (grade
2), and severe abnormalities (grade 3) (Table 2).
When measuring BMD with DEXA, for the T-score
(expressing the relationship with healthy individuals at
the peak of BMD) we considered the acknowledged
levels of -1 and -2.5, while for the Z-score (expressing
the relationship with healthy individuals of the same
age) we introduced the -1.5 threshold level in addition
to the conventional -1 level, to indicate increasing
severity in BMD reduction (Table 2).
The presence of osteonecrosis and/or of pathological
fractures was also considered in the new score since
they contribute to the severity of the disease. The term
osteonecrosis includes lesions occurring in the metaph-
ysis/diaphysis of the bone (bone or medullary infarct)
and lesions in the epiphysis (avascular necrosis). Although
MRI cannot evaluate bone changes per se (as the miner-
al content is virtually unresponsive to magnetic field
stimulation), it is nevertheless highly sensitive for
demonstrating early osteonecrosis. If unrecognized and
untreated, osteonecrosis can progress to cortical col-
lapse and degenerative joint disease, with consequent
increase in pain and disability and need for joint replace-
ment. Avascular necrosis, probably the most clinically
significant and disabling skeletal manifestation of
Gaucher disease, affects predominantly the femoral
head and the proximal humerus and frequently follows
one or more bone crises. Both osteopenia and
osteonecrosis appear to predispose patients to patholog-
ical fractures, and the most affected sites are the verte-
bral bodies (causing vertebral collapse) and the long
bones. The GauSSI-I takes into account the presence of
medullary infarcts (score 1), avascular necrosis (score 3)
and disabling necrosis requiring arthroplasty (score 4) as
damage indicators and prognostic factors with a pro-
found impact on the quality of life of patients with
Gaucher disease. The GauSSI-I assigns additional points
(score 2) when bone fractures are present (Table 3).
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Table 1. Equivalence of the new categories of disease severity
(Normalized score, first column on the left of each panel) pro-
posed for the magnetic resonance evaluation and for scintigraph-
ic evaluation of bone marrow involvement in patients with
Gaucher disease.
Normalized Rosenthal Dusseldorf Terk VDR BMB
score score scorea score score
0 0 0 0 >2.0 0-2
1 1-3 1-3 1a/b 1.5-2.0 3-7
2 4-7 4-6 2a/b 1.0-1.5 8-12
3 8-11 7-8 3a/b <1.0 13-16
Normalized QCSI S-MRI 99mTc-sestamibi 99mTc-radiocolloid
score fat fraction score score scoreb
0 >0.30 0-4 0-2 normal
1 0.30-0.25 5-10 3-4 mild
2 0.20-0.25 11-17 5-6 moderate
3 <0.20 18-24 7-8 severe
aThe presence of osteonecrosis is not considered in the bone marrow score per se,
since it indicates involvement of the bone mineral component rather than the
marrow component, which is the primary focus of MRI. bDegree of
impairment in the normal scintigraphic pattern. S-MRI: Spanish magnetic reso-
nance index;. VDR: vertebral disk ratio; BMB: bone marrow burden; QCSI:
quantative chemical shift index.
Table 2. Equivalence of the new categories of disease severity. 
Normalized Hermann’s DEXA BMD
score x-ray score Z-score T-score
0 0 1<Z<0 T>0
1 1 0<Z<-1 0<T<-1
2 2-3 -1<Z<-1.5 -1<T<-2.5











“Normalized score” (first column on the left) proposed for plain radiographic
evaluation (“Hermann’s X-ray score”), for DEXA measurements (“DEXA
BMD”), in patients with Gaucher disease.
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Hematologic domain
Abnormal hematologic parameters are common in
Gaucher disease9 and are used to monitor the natural
history of the disease and response to therapy.22
Hematologic involvement can be quantitative and/or
qualitative, affecting the function of blood elements,
causing pancytopenia, a bleeding tendency, or immuno-
logical disturbances. Pancytopenia in Gaucher disease is
a multifactorial event, in particular with regard to ane-
mia and thrombocytopenia. The increased hemorrhagic
risk in subjects with moderate thrombocytopenia is
often associated with altered platelet function23 and/or
decreased levels of coagulation factors, with a shorten-
ing of the prothrombin time and/or a prolonged activat-
ed partial thromboplastin time. Gaucher disease
patients have an increased risk of infection, presumably
because of reduced specific and non-specific chemotac-
tic activity of neutrophil granulocytes.24 Moreover,
chronic stimulation of the immune system from the
accumulated glucocerebroside might cause persistent
activation of B lymphocytes with consequent hyper-
gammaglobulinemia, which affects about 20% of sub-
jects with Gaucher disease, with an increased risk of
developing multiple myeloma.25 In the GauSSI-I, the
hematologic domain scores anemia (score 0–3), throm-
bocytopenia (score 0–3), leukopenia (score 0–3) and
abnormalities of hemostasis (score 0–1) separately. For
both leukocyte and platelet counts, a indicates non-
splenectomized patients and b denotes prior splenecto-
my. Although cytopenia in a splenectomized patient
indicates more severe disease (being the result of
reduced production solely), it was agreed that a notation
b does not translate into an actual increase of the numer-
ical score. Measurement of the bleeding time, using the
standardized Ivy technique, allows a combined evalua-
tion of vascular hemostasis and thrombocytic hemosta-
sis and, therefore, of the risk of early bleeding.26 The
normal bleeding time is between 3-8 minutes; therefore,
score 0 is assigned to a bleeding time shorter than 8
minutes, and score 1 to any bleeding time longer than 8
minutes (Table 3).
Biomarker domain
Although serum levels of several biological markers
have been used to evaluate the severity and progression
of Gaucher disease, as well as the efficacy of therapy,
chitotriosidase and CCL18/PARC (pulmonary activat-
ed-related chemokine) are currently the two most wide-
ly acknowledged reliable biomarkers.27
Chitotriosidase activity in serum can increase 100-
4,000-fold over the normal values in Gaucher disease,
and is reduced by therapy. However, 5-6% of the gen-
eral population are homozygous for a chitotriosidase
gene mutation causing complete deficiency of the
enzyme activity, while approximately 35% of the gen-
eral population are heterozygous for the mutation.28
Chitotriosidase measurements are unreliable in these
situations. The serum levels of chemokine
CCL18/PARC, which are not affected by any known
genetic abnormality, are increased 10-40 fold over the
normal levels in Gaucher disease and decrease during
therapy with a pattern similar to that of chitotriosi-
M. Di Rocco et al. 
Table 3. GauSSI-I.
Skeletal domain
Bone marrow infiltration (based on either MRI or scintigraphic





Impairment of mineral component (based on either DEXA 















> 12 g/dL (male) > 11.5 (female) 0
between 10-12 g/dL 1
between 8-9.9 g/dL 2
<8 g/dL* 3
(*) or need for blood transfusion
White blood cell count
>4×109/L 0
between 2.5-4×109/L 1 a/b
< 2.5×109/L 2 a/b
< 1.9×109/L 3 a/b
Platelet count
> 150×109 L 0
between 101-150×109/L 1 a/b
between 60-100×109/L 2 a/b
< 60×109/L 3 a/b
Bleeding time
< 8 min 0
> 8 min 1
Biomarker domain
Serum chitotriosidase or CCL18
Chitotriosidase < 600 nmol/mL × h score 0
Chitotriosidase 600-4,000 nmol/mL × h score 1
Chitotriosidase 4,001-15,000 nmol/mL × h score 2
Chitotriosidase > 15,000 nmol/mL × h score 3
CCL18 <72 ng/mL score 0
CCL18 72-236 ng/mL score 1
CCL18 237-1000 ng/mL score 2
CCL18 > 1000 ng/mL score 3
Visceral domain
Spleen
no MR/US lesions 0
MR/US lesions 3 (as defined in text)
no splenectomy 0
splenectomy 2
volume <5 N 0
between 5-9 N 1
between 10-15 N 2
volume >15 N 3
Liver
no hepatic disease 0 (as defined in text)
hepatic disease 3 (as defined in text)
volume <1.25 N 0
between 1.25-2.5 N 1














MRI: magnetic resonance; US: ultrasound; N: normal.
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dase.29 The normal serum activity of chitotriosidase is 4-
76 nmol/mL/hour, while in the Gaucher population lev-
els in the 300-65,000 nmol/mL/hour range have been
described. The normal serum levels of CCL18 are
between 10-72 ng/mL, and in the Gaucher population a
range of 237-2285 ng/mL (with a median of 948 ng/mL)
has been reported. Only one biomarker (either chito-
triosidase or CCL18/PARC) is employed in the GauSSI-
I and chitotriosidase is used only after exclusion of
homozygous or heterozygous mutations (Table 3).
Visceral domain 
According to the Gaucher Registry, hepatospleno-
megaly at diagnosis is very common.30 Organ volumes
should be measured by quantitative imaging (preferably
MRI, otherwise computed tomography [CT] or ultra-
sound when MRI is not available), not merely by phys-
ical examination. Volumetric CT and MRI are both
more accurate than conventional two-dimensional
ultrasound, particularly when applied to irregularily
shaped or large organs.31-33 MRI has greater sensitivity
and specificity than CT or ultrasound for the study of
parenchyma, especially for detecting focal lesions in the
liver and spleen. Abdominal thin-slice axial images are
used to calculate visceral volumes with great accuracy.
Splenomegaly is defined as a splenic mass greater
than the normal 0.2% of total body weight in kilo-
grams. In untreated Gaucher disease spleen size can
reach 100-times the normal volume. The most reliable
methods to assess spleen enlargement are CT and MRI,
which allow evaluation of the volume in milliliters (the
normal volume being about 150 mL in an adult subject
of standard body weight). A description of the spleen
morphology is also important in the assessment of
Gaucher patients, since fibrotic scarring, infarcts and
hematologic malignancies can be present (Table 3).
Hepatomegaly is defined as a liver mass greater than
1.25 times the normal 2.5% of total body weight in kilo-
grams, and hepatomegaly >2.5 times normal is a severe
risk factor for an untoward outcome of Gaucher disease.
Abnormal biochemical tests of liver function require a
further diagnostic survey for other concomitant hepatic
disease, i.e., viral or toxic hepatitis, autoimmune hepati-
tis or other metabolic liver disease. GauSSI-I takes into
account the degree of hepatomegaly and possible liver
pathology related to Gaucher disease, such as hepatic
fibrosis and portal hypertension (Table 3).
Lung domain
Pulmonary disease is a possible complication of type
I Gaucher disease, although its incidence and pattern of
progression are not yet well established.34 Signs consist
of airway obstruction with reduced expiratory flow;
reduced lung volume and reduced alveolar-capillary dif-
fusion.35 Lung involvement can be investigated through
chest X-ray, pulmonary function tests, high-resolution
CT of the chest and oxygen saturation in arterial blood.
Pulmonary hypertension is the most severe lung com-
plication in Gaucher patients. Its exact pathophysiology
is still debated, but seems mostly linked to prior
splenectomy in type 1 Gaucher patients. The GauSSI-I
score considers pulmonary involvement only when pul-
monary hypertension is present. Accepted criteria are
employed, which define pulmonary arterial hyperten-
sion in other underlying conditions as well, assuming
that the cardiac ejection fraction is normal.
An additional score used in the lung domain is
assigned to respiratory failure documented by pul-
monary function tests; this score ranges from 0 to 2 and
is employed after excluding possible concomitant caus-
es of respiratory failure other than Gaucher disease
(Table 3). 
Neurological domain
Although type I Gaucher disease has classically been
defined as chronic non-neuronopathic, there is growing evi-
dence of a correlation between carriership of one or two
mutations for Gaucher disease and parkinsonism or
Parkinson’s disease.36,37 Initial oversight of subtle supra-
nuclear gaze palsy in mild type III disease and/or the
possible association being linked mainly in Ashkenazi
Jewish populations, but not in other populations,38 may
be alternative explanations for the recent epidemiologi-
cal observations. Reports suggest that peripheral neu-
ropathy may be a late manifestation in Gaucher disease;
this has led to a suggestion to assess motor conduction
velocity in patients with type I Gaucher disease when
peripheral neuropathy is suspected on clinical grounds.39
The GauSSI-I score value proposed for central and
peripheral neurological involvement ranges from 0 to 3
(Table 3).
Comparative evauation of GauSSI-I and Zimran SSI
Study procedures conformed to our institutions’
guidelines for human studies and all patients provided
informed written consent. We retrospectively examined
a total of 53 adult patients with type I Gaucher disease
for whom all clinical, biochemical and imaging data
were available for about 2 years apart, computing the
two scores at two different time-points. Data sets on 30
women and 23 men, with a mean age of 39±15 years
(range, 18-85), were available. The average age of the
patients when the first symptoms of Gaucher disease
appeared and were reason to consult a physician was
14±10 years (range, 2-50), while the average age at the
time of diagnosis of Gaucher disease was 23±16 years
(range, 2-69). The most common mutation was N370S
(total of 56/106 alleles), followed by L444P (13 alleles).
Twenty-two patients had never received ERT at inclu-
sion for the baseline assessment for this validation,
whereas the other 31 patients had already been receiv-
ing imiglucerase for a mean of 21±12 months (median
21; range, 3-78), with a mean dose of 41±14 U/kg body
weight per month (median 37; range, 21-60), at the
baseline assessment. After the baseline evaluation, all
ERT-naive patients also started enzyme treatment.
Thus, at the follow-up validation assessment (per-
formed after a mean of 30±17 months, median 24, range
12-86), all 53 patients had been treated with imiglu-
cerase (mean dose 44±16 U/kg body weight per month,
median 42, range 20-90).
The first step in the comparative evaluation of the
Zimran severity score index (SSI) score and the GauSSI-
I, estimating the ability to reflect changes in disease
A new type I Gaucher disease severity score index 
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severity induced by ERT, was to normalize each set of
data to the maximum possible values of the two scores
(51 for the Zimran SSI and 42 for the GauSSI-I). Such
normalization was performed in order to avoid possible
biases in the evaluation of follow-up versus baseline dif-
ferences in severity scores due to the different scales of
the two scoring systems. A new set of data was, there-
fore, generated, in which each patient’s score (both at
baseline and at follow-up evaluation) was expressed as
a fraction of the possible maximum score (51 in the case
of  the Zimran SSI and 42 in the case of GauSSI-I). After
this normalization, the two scores remained non-para-
metric, as were the original Zimran score and GauSSI-I
values.
Results
The GauSSI-I described in this paper has a maximum
of 42 points, distributed over six different domains with
unequally weighted parameters:
- skeletal domain (bone marrow infiltration and bone
mineral component subdomains) (maximum com-
bined score: 11);
- hematologic domain (maximum score: 10);
- biomarker domain (maximum score: 3);
- visceral domain (maximum score: 11);
- lung domain (maximum score: 4); 
- neurological domain (maximum score: 3) (Table 3).
This score can only be used in adults since the meas-
urement of bone marrow infiltration is not validated in
children.
In comparison with the Zimran score, the weight of
hematologic domain involvement was increased by our
consensus group whereas  the influence of visceral
involvement was reduced. The weight of bone involve-
ment, which is one of the most important and debilitat-
ing complications of type I Gaucher disease, having a
greater impact on quality of life than hematologic and
visceral manifestations, was increased from 17% to
27%. The percent weight of neurological involvement
was reduced from 39% to 7% because in type I
Gaucher disease neurological involvement is rare, still
contentious, and less severe than in type II and III dis-
ease. A domain for biological markers, reflecting total
burden of Gaucher cells or substrate storage, was intro-
duced de novo; these parameters were not available
when the Zimran score was originally published.
As a general proof of concept, the GauSSI-I was com-
pared with the Zimran SSI score, under the hypothesis
that the new score would reflect variations in disease
severity induced by treatment more readily than the SSI
score. 
Spearman’s correlation test revealed that in the over-
all group of 53 patients the two scores were highly cor-
related with each other both at baseline (R=0.729,
p<0.00001) and at follow-up (R=0.806, p<0.00001).
Using Wilcoxon’s test, it was demonstrated that both
scores measure reductions induced by ERT in the fol-
low-up versus the baseline values very well: the mean
normalized SSI score at follow-up (0.135±0.013 SEM)
was significantly lower than the corresponding baseline
value (0.189±0.012 SEM, p<0.00001), and similarly the
mean follow-up normalized GauSSI-I value was signifi-
cantly lower than the corresponding baseline value
(0.150±0.013 SEM versus 0.257±0.015 SEM, p<0.00001)
(Figure 1).
The final step in the comparison was to test the
hypothesis that the GauSSI-I would reflect changes in
disease severity induced by ERT more readily than the
Zimran SSI score. To this purpose, the distribution of
the changes observed in each patient between follow-
up and baseline scores was analyzed for each set of
data (Zimran score and GauSSI-I), and these distribu-
tions were found to be of a Gaussian-type pattern. The
one-tail paired t test, employed to compare the reduc-
tions in normalized scores induced by ERT between
the scores, showed that the mean change from baseline
to follow-up observed with the GauSSI-I (0.107±0.010
SEM) was significantly greater (by a factor of almost 2)
than the equivalent change observed using the SSI
(0.054±0.006 SEM, p<0.00001). This result confirms
that the GauSSI-I is a more sensitive method than the
Zimran score for measuring changes in disease severity
caused by therapy.
Discussion 
The superiority of GauSSI-I is presumably due to the
SSI assigning more weight (almost 55% of maximum
total score) to complications of the disease (e.g.,
splenectomy, fractures, and central nervous system
involvement) that will not change with cause-specific
M. Di Rocco et al. 
Figure 1. Plot of the changes in the mean Zimran’s severity score
index (SSI) and in the new index proposed here (GauSSI-I) versus
baseline observed in 53 patients following ERT administered for
an average period of 30 months (± SEM bars are also indicated).
For the purposes of statistical comparison and analysis, both sets
of data (SSI and GauSSI-I) were normalized to the maximun pos-
sible score for each index (51 for SSI and 42 for GauSSI-I). While
both scores demonstrate highly significant improvement induced
by ERT (p<0.00001 in both instance), the fractional reduction of
the GauSSI-I is significantly greater (almost 2-fold) than that of
the SSI (0.117 ± 0.011 SEM versus 0.054 ± 0.006 SEM,
p<0.00001). This translates graphically into the slope of the
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therapy. Instead, GauSSI-I assigns only about 19% of
the total score to such abnormalities, while the majori-
ty of the total index points are assigned to manifesta-
tions that are amenable to treatment. Since a validation
of the GauSSI-I was beyond the scope of the current
study, a limitation of this instrument remains that it is
not validated. However a validated Gaucher disease
severity scoring tool is not currently available. In future
studies GauSSI-I will be validated against established
standards for measuring clinical changes, such as the
Short Form-36.
If the applicability of GauSSI-I is confirmed by further
testing in larger groups of patients, then the accuracy
and sensitivity of GauSSI-I may allow its use in the
determination of individualized therapeutic regimens.
This proposed score may also become a crucial param-
eter for assessing the efficacy of new therapies for
Gaucher disease, such as substrate reduction or molecu-
lar chaperones, during clinical trials. The GauSSI-I could
also be used as a model for developing similar scores in
other lysosomal storage diseases for which effective
treatments have or will soon become available.
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